Metabolism and excretion of rivaroxaban, an oral, direct factor xa inhibitor, in rats, dogs, and humans

Drug Metabolism and Disposition

Volumn 37, Issue 5, 2009, Pages 1056-1064

  Weinz, C ^a   Schwarz, T ^a   Kubitza, D ^a   Mueck, W ^a   Lang, D ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DRUG METABOLITE; LACTAM; MORPHOLINONE; RIVAROXABAN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXPERIMENTAL DOG; HUMAN; HUMAN EXPERIMENT; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; ANIMALS; AREA UNDER CURVE; BILE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FECES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MIDDLE AGED; MORPHOLINES; RATS; RATS, WISTAR; SPECIES SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET; TANDEM MASS SPECTROMETRY; THIOPHENES;

CANIS FAMILIARIS; RATTUS;

EID: 66449099711     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.025569     Document Type: Article

References (11)

1. Biemond BJ, Perzborn E, Friederich PW, Levi M, Buetehorn U, and Biiller HR (2007) Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 59-7939)-an oral, direct factor Xa inhibitor. Thromb Haemost 97:471-477.
2. Depasse F, Busson J, Mnich J, Le Flem L, Gerotziafas GT, and Samama MM (2005) Effect of BAY 59-7939-a novel, oral, direct factor Xa inhibitor-on clot-bound factor Xa activity in vitro. J Thromb Haemost 3 (Suppl 1):P1104.
3. Gerotziafas GT, Elalamy I, Chakroun T, Perzborn E, Depasse F, and Misselwitz F (2005) The oral, direct factor Xa inhibitor BAY 59-7939 inhibits thrombin generation in vitro after tissue factor pathway activation. J Thromb Haemost 3(Suppl 1):P2295.
4. Kubitza D, Becka M, Voith B, Zuehlsdorf M, and Wensing G (2005a) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:412-421.
5. Kubitza D, Becka M, Wensing G, Voith B, and Zuehlsdorf M (2005b) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873-880.
6. Lang D, Freudenberger C, and Weinz C (2009) In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos 37:1046-1055.
7. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, and Straub A (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factor Xa inhibitor. J Thromb Haemost 3:514-521.
8. 14C]BAY 59-7939 and its radiolabeled metabolite M-4. J Label Compd Radiopharm 49:929-934.
9. f-({(5.S')-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3- oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 48:5900-5908.
10. Weinz C, Buetehorn U, Daehler HP, Kohlsdorfer C, Pleiss U, Sandmann S, Schlemmer KH, Schwarz T, and Steinke W (2005) Pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-in rats and dogs. Xenobiotica 35:891-910.
11. Yamaoka K, Nakagawa T, and Uno T (1978) Statistical moments in pharmacokinetics. J Pharacokinet Biopharm 6:547-558.